Antibody therapies for the prevention and treatment of viral infections

npj Vaccines

Volumn 2, Issue 1, 2017, Pages

  Salazar, Georgina ^a   Zhang, Ningyan ^a   Fu, Tong Ming ^b   An, Zhiqiang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85042287795     PISSN: None     EISSN: 20590105     Source Type: Journal    
DOI: 10.1038/s41541-017-0019-3     Document Type: Review

References (157)

1. Ehrlich, P. Partial cell functions-Nobel lecture, December 11, 1908 in Physiology or Medicine: Including Presentation Speeches and Laureates' Biographies. 304-320 (Elsevier Publisher, 1908).
2. Winau, F., Westphal, O., Winau, R. Paul Ehrlich-in search of the magic bullet. Microbes Infect. 6, 786-789 (2004).
3. Stangel, M., Pul, R. Basic principles of intravenous immunoglobulin (IVIg) treatment. J. Neurol. 253, V18-24 (2006).
4. Kohler, G., Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
5. Throsby, M., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+memory B cells. PLoS ONE 3, e3942 (2008).
6. Meng, W., et al. Rapid generation of human-like neutralizing monoclonal antibodies in urgent preparedness for influenza pandemics and virulent infectious diseases. PLoS ONE 8, e66276 (2013).
7. Harvey, B. R., et al. Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc. Natl Acad. Sci. U.S.A. 101, 9193-9198 (2004).
8. Bowley, D. R., Labrijn, A. F., Zwick, M. B., Burton, D. R. Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. Protein Eng. Des. Sel. 20, 81-90 (2007).
9. Smith, E. S., Zauderer, M. In Therapeutic Monoclonal Antibodies: From bench to Clinic (ed. Z. An) 283-307 (John Wiley & Sons, 2009).
10. Huang, J., et al. Isolation of human monoclonal antibodies from peripheral blood B cells. Nat. Protoc. 8, 1907-1915 (2013).
11. Walker, L. M., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
12. Scheid, J. F., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636-640 (2009).
13. Traggiai, E., et al. An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat. Med. 10, 871-875 (2004).
14. Reddy, S. T., et al. Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells. Nat. Biotechnol. 28, 965-969 (2010).
15. Wrammert, J., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667-671 (2008).
16. Meng, W., et al. Efficient generation of monoclonal antibodies from single rhesus macaque antibody secreting cells. MAbs 7, 707-718 (2015).
17. Cheung, W. C., et al. A proteomics approach for the identification and cloning of monoclonal antibodies from serum. Nat. Biotechnol., doi:nbt.2167 [pii], 10.1038/nbt.2167 (2012).
18. Wine, Y., et al. Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response. Proc. Natl Acad. Sci. U.S.A. 110, 2993-2998 (2013).
19. McDaniel, J. R., DeKosky, B. J., Tanno, H., Ellington, A. D., Georgiou, G. Ultra-high-throughput sequencing of the immune receptor repertoire from millions of lymphocytes. Nat. Protoc. 11, 429-442 (2016).
20. DeKosky, B. J., et al. In-depth determination and analysis of the human paired heavy- A nd light-chain antibody repertoire. Nat. Med. 21, 86-91 (2015).
21. Miller, M. D., et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl Acad. Sci. U.S.A. 102, 14759-14764 (2005).
22. Corti, D., Lanzavecchia, A. Efficient methods to isolate human monoclonal antibodies from memory b cells and plasma cells. Microbiol. Spectr. 2, doi: 10.1128/microbiolspec.AID-0018-2014 (2014).
23. Wang, Q., et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci, Transl. Med. 8, 369ra179, doi: 10.1126/scitranslmed.aai8336 (2016).
24. Gilman, M. S. A., et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci. Immunol. 1, doi: 10.1126/sciimmunol.aaj1879 (2016).
25. Scherer, E. M., et al. Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. PLoS Pathog. 10, e1004461 (2014).
26. Sundling, C., et al. Single-cell and deep sequencing of IgG-switched macaque B cells reveal a diverse Ig repertoire following immunization. J. Immunol. 192, 3637-3644 (2014).
27. Ueki, Y., et al. Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J. Exp. Med. 171, 19-34 (1990).
28. Bernasconi, N. L., Traggiai, E., Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199-2202 (2002).
29. Corti, D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
30. Smith, K., et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 4, 372-384 (2009).
31. Wrammert, J., et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J. Virol. 86, 2911-2918 (2012).
32. Nakamura, G., et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe. 14, 93-103 (2013).
33. Dejnirattisai, W., et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170-177 (2015).
34. Wrammert, J., et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181-193 (2011).
35. Sundling, C., Phad, G., Douagi, I., Navis, M., Karlsson Hedestam, G. B. Isolation of antibody V(D)J sequences from single cell sorted rhesus macaque B cells. J. Immunol. Methods 386, 85-93 (2012).
36. Demberg, T., et al. Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J. Virol. 86, 12591-12604 (2012).
37. Jin, A., et al. A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. Nat. Med. 15, 1088-1092 (2009).
38. Sato, S., et al. Proteomics-directed cloning of circulating antiviral human monoclonal antibodies. Nat. Biotechnol. 30, 1039-1043 (2012).
39. Boutz, D. R., et al. Proteomic identification of monoclonal antibodies from serum. Anal. Chem. 86, 4758-4766 (2014).
40. Wu, X., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602 (2011).
41. Zhu, J., et al. Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc. Natl Acad. Sci. USA, doi: 10.1073/pnas.1219320110 (2013).
42. Dekosky, B. J., et al. High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat. Biotechnol., doi: 10.1038/nbt.2492 (2013).
43. Fu, T. M., An, Z., Wang, D. Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine 32, 2525-2533 (2014).
44. Wang, D., et al. A replication-defective human cytomegalovirus vaccine for prevention of congenital infection. Sci. Transl. Med. 8, 362ra145 (2016).
45. Komatsu, T. E., Pikis, A., Naeger, L. K., Harrington, P. R. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: A comprehensive review of putative resistance pathways. Antiviral Res. 101, 12-25 (2014).
46. Houldcroft, C. J., et al. Detection of low frequency multi-drug resistance and novel putative maribavir resistance in immunocompromised pediatric patients with cytomegalovirus. Front. Microbiol. 7, 1317 (2016).
47. Revello, M. G., et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N. Engl. J. Med. 370, 1316-1326 (2014).
48. Dole, K., et al. A first-in-human study to assess the safety and pharmacokinetics of monoclonal antibodies against human cytomegalovirus in healthy volunteers. Antimicrob. Agents Chemother., doi: 10.1128/AAC.02698-15 (2016).
49. Ishida, J. H., et al. Phase 1 randomized, double-blind, placebo-controlled study of RG7667, an anticytomegalovirus combination monoclonal antibody therapy, in healthy adults. Antimicrob. Agents Chemother. 59, 4919-4929 (2015).
50. Freed, D. C., et al. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc. Natl Acad. Sci. U.S.A. 110, E4997-5005 (2013).
51. Ohlin, M., Soderberg-Naucler, C. Human antibody technology and the development of antibodies against cytomegalovirus. Mol. Immunol., doi: 10.1016/j.molimm.2015.02.026 (2015).
52. Macagno, A., et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J. Virol. 84, 1005-1013 (2010).
53. Patel, H. D., et al. In vitro characterization of human cytomegalovirus-targeting therapeutic monoclonal antibodies LJP538 and LJP539. Antimicrob. Agents Chemother. 60, 4961-4971 (2016).
54. Novartis. A. Multi-center, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of CSJ148 Compared to Placebo to Prevent Human Cytomegalovirus (HCMV) Replication in Stem Cell Transplant Patients. NCT02268526 (ClinicalTrials.gov), 2016).
55. Li, B., et al. In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation. MAbs 6, 437-445 (2014).
56. Borucki, M. J., et al. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 64, 103-111 (2004).
57. Manley, K., et al. Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe 10, 197-209 (2011).
58. Ishida, J. H., et al. Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients. Antimicrob. Agents Chemother. (2016).
59. Mc Mahon, A., Martin-Loeches, I. The pharmacological management of severe influenza infection-'existing and emerging therapies'. Expert Rev. Clin. Pharmacol. 10, 81-95 (2017).
60. Pappas, L., et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516, 418-422 (2014).
61. Krammer, F. Novel universal influenza virus vaccine approaches. Curr. Opin. Virol. 17, 95-103 (2016).
62. Gupta, P., et al. Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. MAbs 8, 991-997 (2016).
63. Lim, J. J., et al. Two phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose studies to investigate the safety, tolerability, and pharmacokinetics of an anti-influenza A virus monoclonal antibody, MHAA4549A, in healthy volunteers. Antimicrob. Agents Chemother. 60, 5437-5444 (2016).
64. Genentech. A. Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults. NCT02623322 (ClinicalTrials.gov), 2016).
65. Genentech. A. Study of MHAA4549A in Combination with Oseltamivir Versus Oseltamivir in Participants with Severe Influenza A Infection. NCT02293863 (ClinicalTrials.gov), 2016).
66. Naik, G. Scientists' elusive goal: Reproducing study resutls. (Wall Street Journal, 2015).
67. Baranovich, T., et al. The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute respiratory distress syndrome. Antimicrob. Agents Chemother. 60, 2118-2131 (2016).
68. Wollacott, A. M., et al. Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks. EBioMedicine 5, 147-155, doi: 10.1016/j.ebiom.2016.02.021 (2016).
69. Visterra. A. Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects with Uncomplicated Influenza A Infection. NCT02989194 (ClinicalTrials.gov), 2016).
70. Ekiert, D. C., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251 (2009).
71. NIAID. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Human Challenge Model. NCT02371668 (ClinicalTrials.gov), 2016).
72. Ekiert, D. C., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843-850 (2011).
73. Crucell. Randomised, Double-Blind, Placebo-Controlled, Phase IIa Study in Healthy Volunteers to Evaluate the Protective Efficacy and Safety of CR8020 in an Influenza Challenge Model. NCT01938352 (ClinicalTrials.gov), 2014).
74. Tharakaraman, K., Subramanian, V., Cain, D., Sasisekharan, V., Sasisekharan, R. Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. Cell Host Microbe 15, 644-651 (2014).
75. Grandea, A. G. 3rd, et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc. Natl Acad. Sci. U.S.A. 107, 12658-12663 (2010).
76. Ramos, E. L., et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J. Infect. Dis. 211, 1038-1044 (2015).
77. Smith, S. A., Derdeyn, C. A. Harnessing the protective potential of HIV-1 neutralizing antibodies. F1000Research 5, doi: 10.12688/f1000research.7254.1 (2016).
78. Klein, F., et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199-1204 (2013).
79. CytoDyn. A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/Optimized Background Therapy in Treatment-Experienced HIV Subjects (PRO 140). NCT02483078 (ClinicalTrials.gov), 2016).
80. Escolano, A., Dosenovic, P., Nussenzweig, M. C. Progress toward active or passive HIV-1 vaccination. J. Exp. Med. doi: 10.1084/jem.20161765 (2016).
81. Gray, G. E., Laher, F., Lazarus, E., Ensoli, B., Corey, L. Approaches to preventative and therapeutic HIV vaccines. Curr. Opin. Virol. 17, 104-109 (2016).
82. Marasco, W. A., Sui, J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol. 25, 1421-1434 (2007).
83. Zhou, T., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010).
84. Scharf, L., et al. Structural basis for germline antibody recognition of HIV-1 immunogens. Elife 5, doi: 10.7554/eLife.13783 (2016).
85. Ledgerwood, J. E., et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin. Exp. Immunol. 182, 289-301 (2015).
86. Bar, K. J., et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037-2050 (2016).
87. NIAID. Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex with Men. NCT02716675 (ClinicalTrials.gov), 2016).
88. NIAID. Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women. NCT02568215 (ClinicalTrials.gov), 2016).
89. NIAID. Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection. NCT02664415 (ClinicalTrials.gov), 2016).
90. Scheid, J. F., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
91. Shingai, M., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277-280 (2013).
92. Caskey, M., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487-491 (2015).
93. Scheid, J. F., et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556-560 (2016).
94. Schoofs, T., et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997-1001 (2016).
95. University, R. 3BNC117 and 10-1074 in HIV Uninfected Adults. NCT02824536 (ClinicalTrials.gov), 2016).
96. University, R. 3BNC117 and 10-1074 in HIV-Infected Individuals. NCT02825797 (ClinicalTrials.gov), 2016).
97. University, R. A Phase I/II Single Site Open Label Trial of the Safety and Antiviral Activity of C2F5, C2G12, and C4E10 Monoclonal Antibody Infusions in Well-Suppressed HAART-Treated Individuals Treated During Acute and Early HIV-1 Infection. NCT00219986 (ClinicalTrials.gov), 2007).
98. Murga, J. D., Franti, M., Pevear, D. C., Maddon, P. J., Olson, W. C. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 50, 3289-3296 (2006).
99. Jacobson, J. M., et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob. Agents Chemother. 54, 4137-4142 (2010).
100. Henrich, T. J., Kuritzkes, D. R. HIV-1 entry inhibitors: Recent development and clinical use. Curr. Opin. Virol. 3, 51-57 (2013).
101. Pace, C. S., et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc. Natl Acad. Sci. U.S.A. 110, 13540-13545 (2013).
102. Sun, M., et al. Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. J. Acquir. Immune Defic. Syndr. 66, 473-483 (2014).
103. McLellan, J. S., et al. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat. Struct. Mol. Biol. 17, 248-250 (2010).
104. Mejias, A., Ramilo, O. New options in the treatment of respiratory syncytial virus disease. J. Infect. 71, S80-87 (2015).
105. Wu, H., et al. Ultra-potent antibodies against respiratory syncytial virus: Effects of binding kinetics and binding valence on viral neutralization. J. Mol. Biol. 350, 126-144 (2005).
106. Carbonell-Estrany, X., et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: A noninferiority trial. Pediatrics 125, e35-51 (2010).
107. Robbie, G. J., et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob. Agents Chemother. 57, 6147-6153 (2013).
108. Griffin, M. P., et al. Safety, tolerability, and pharmacokinetics of the respiratory syncytial virus-prefusion F-targeting monoclonal antibody with an extended half-life, MEDI8897, in healthy adults. Antimicrob Agents Chemother, doi: 10.1128/AAC.01714-16 (2016).
109. MedImmune. A. Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody with an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants. NCT02878330 (ClinicalTrials.gov), 2016).
110. Regeneron. A. Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants. NCT02325791 (ClinicalTrials.gov), 2016).
111. Broadbent, L., Groves, H., Shields, M. D., Power, U. F. Respiratory syncytial virus, an ongoing medical dilemma: An expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza Other Respir. Viruses 9, 169-178 (2015).
112. Kaner, J., Schaack, S. Understanding Ebola: The 2014 epidemic. Global. Health 12, 53 (2016).
113. Qiu, X., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47-53 (2014).
114. Dodd, L. E., et al. Design of a randomized controlled trial for Ebola virus disease medical countermeasures: PREVAIL II, the Ebola MCM Study. J. Infect. Dis. 213, 1906-1913 (2016).
115. Group, P. I. W., Multi-National, P. I. I. S. T. A randomized, controlled trial of ZMapp for Ebola virus infection. N. Engl. J. Med. 375, 1448-1456 (2016).
116. Cardile, A. P., Downey, L. G., Wiseman, P. D., Warren, T. K., Bavari, S. Antiviral therapeutics for the treatment of Ebola virus infection. Curr. Opin. Pharmacol. 30, 138-143 (2016).
117. Zhang, Q., et al. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci. Rep. 6, 25856 (2016).
118. Bornholdt, Z. A., et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351, 1078-1083 (2016).
119. Krauer, F., et al. zika virus infection as a cause of congenital brain abnormalities and Guillain-Barre syndrome: Systematic review. PLoS Med. 14, e1002203 (2017).
120. Dawes, B. E., et al. Research and development of Zika virus vaccines. Npj Vaccines 1, 16007, doi: 10.1038/npjvaccines.2016.7 (2016).
121. Hampson, K., et al. Estimating the global burden of endemic canine rabies. PLoS Negl. Trop. Dis. 9, e0003709 (2015).
122. Jackson, A. C. Human rabies: A 2016 update. Curr. Infect. Dis. Rep. 18, 38 (2016).
123. Bakker, A. B., et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: Safety, tolerability, and neutralizing activity. Vaccine 26, 5922-5927 (2008).
124. Dietzschold, B., et al. Biological characterization of human monoclonal antibodies to rabies virus. J. Virol. 64, 3087-3090 (1990).
125. Marissen, W. E., et al. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: Fine mapping and escape mutant analysis. J. Virol. 79, 4672-4678 (2005).
126. Bakker, A. B., et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J. Virol. 79, 9062-9068 (2005).
127. A Single-blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-exposure Prophylaxis in Children and Adolescents. NCT00708084 (ClinicalTrials.gov), 2012).
128. A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects. NCT00656097 (ClinicalTrials.gov), 2011).
129. Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults. NCT01228383 (ClinicalTrials.gov), 2013).
130. Sloan, S. E., et al. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 25, 2800-2810 (2007).
131. Wang, Y., et al. G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates. Antiviral Res. 91, 187-194 (2011).
132. De Benedictis, P., et al. Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. EMBO Mol. Med. 8, 407-421 (2016).
133. Hospital, B. D. A Study of the Interruption on the Mother-to-child Transmission of Hepatitis B Virus (HBV MTCT)in Newborns at High Risk. ClinicalTrials.gov, NCT02901418 (2016).
134. Zhang, T. Y., et al. Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut 65, 658-671 (2016).
135. Wang, W., et al. A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effect. MAbs 8, 468-477 (2016).
136. Fibriansah, G., Lok, S. M. The development of therapeutic antibodies against dengue virus. Antiviral Res. 128, 7-19 (2016).
137. Thomas, S. J., Endy, T. P. Critical issues in dengue vaccine development. Curr. Opin. Infect. Dis. 24, 442-450 (2011).
138. Varani, S., Landini, M. P. Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae 2, 6 (2011).
139. de Oliveira Poersch, C., et al. Dengue virus infections: Comparison of methods for diagnosing the acute disease. J. Clin. Virol. 32, 272-277 (2005).
140. Deen, J., Weber, M. W., Jaenisch, T. Dengue in the context of the integrated management of childhood illness. PLoS Negl. Trop. Dis. 10, e0004838 (2016).
141. Screaton, G., Mongkolsapaya, J., Yacoub, S., Roberts, C. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 15, 745-759 (2015).
142. Fibriansah, G., et al. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349, 88-91 (2015).
143. Fibriansah, G., et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol. Med. 6, 358-371 (2014).
144. Lai, C. J., et al. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J. Virol. 81, 12766-12774 (2007).
145. Shrestha, B., et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 6, e1000823 (2010).
146. Teoh, E. P., et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med. 4, 139ra183 (2012).
147. Smith, S. A., et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. mBio 4, e00873-00813 (2013).
148. Robinson, L. N., et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. Cell 162, 493-504 (2015).
149. Williams, K. L., et al. Therapeutic efficacy of antibodies lacking Fcgamma receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog. 9, e1003157 (2013).
150. Ramadhany, R., et al. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection. Antiviral Res. 124, 61-68 (2015).
151. Beltramello, M., et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271-283 (2010).
152. Both, L., et al. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine 31, 1553-1559 (2013).
153. Welburn, S. C., Coleman, P. G., Zinsstag, J. Rabies control: Could innovative financing break the deadlock? Front. Vet. Sci. 4, 32 (2017).
154. Baccam, P., Beauchemin, C., Macken, C. A., Hayden, F. G., Perelson, A. S. Kinetics of influenza A virus infection in humans. J. Virol. 80, 7590-7599 (2006).
155. Bournazos, S., Ravetch, J. V. Anti-retroviral antibody FcgammaR-mediated effector functions. Immunol. Rev. 275, 285-295 (2017).
156. Deal, C. E., Balazs, A. B. Engineering humoral immunity as prophylaxis or therapy. Curr. Opin. Immunol. 35, 113-122 (2015).
157. Flingai, S., et al. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci. Rep. 5, 12616 (2015).